Kardigan private stock trade

Kardigan

Legal NameKardigan, Inc.
HeadquartersSouth San Francisco, CA
SectorBioTech

Kardigan is a biotechnology company developing precision medicines to transform the treatment of cardiovascular disease. Its platform modernizes cardiovascular drug development by combining AI-driven insights with clinical trial data to match critical disease drivers with treatment responders. Kardigan focuses on creating therapies that move beyond symptom management toward functional cures, targeting conditions such as genetic dilated cardiomyopathy and other inherited heart diseases. By leveraging “Cardiac Intelligence,” the company builds a portfolio of personalized medicines designed to modify underlying disease pathophysiology, aiming to make cardiovascular disease preventable, curable, and no longer the leading cause of death worldwide.

Learn more about Kardigan IPO.

Secondary Pricing Information

$ .star in blue circleZX Index Value | Get Access
pricing graph placeholder
star in blue circleTo view Pre-IPO pricing data for and trade Kardigan, contact us to request access.
<

Secondary Volume Information

$ .M star in blue circleAggregate Volume | Get Access
volume graph placeholder
star in blue circleTo view Pre-IPO volume data for and trade Kardigan, contact us to request access.
View More

ZXData is a leading provider of real-time secondary data on private companies. ZXData's dataset incoroporates closed trades with 20bn+ in volume. In addition, it incorporates $200bn+ of buy/sell prices and $70bn+ of reported marks to provide private market investors, trading desks, lenders, and companies with unprecedented market intelligence on private companies.

Disclaimer

This report is provided for informational purposes only and does not constitute a recommendation or solicitation to buy or sell any financial instrument or to participate in any trading strategy and should not be construed as such. The values shown in this report are not indicative price quotations. This report does not constitute investment advice, nor does this report constitute a "research report" as defined by FINRA Rule 2241 or a "debt research report" as defined by FINRA Rule 2242.

The ZXData and the information contained in this report, some of which have been obtained from third-party sources, are provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. Neither Zanbato Inc. (“Zanbato”) nor its affiliates guarantee the accuracy or completeness of the data contained in this report, or its computation and compilation.

The ZXData and this report constitute Zanbato’s valuable intellectual property. You are expressly prohibited from copying, modifying, transmitting or redistributing the ZXData or this report without Zanbato’s prior written consent.